Resonant acquires Labfish to enhance its European clinical trial infrastructure, adding specialized calibration and global partner depot capabilities to its service portfolio.
The acquisition by Resonant integrates Labfish's specialized calibration expertise and IOR/EOR coverage into a global clinical solutions platform. This strategic move significantly expands Resonant's European footprint and enhances the end-to-end support capabilities for the clinical trial lifecycle.
Labfish contributes specialized calibration expertise, IOR/EOR coverage, and partner depots to support global clinical trials.
The acquisition aims to expand Resonant's European presence and provide comprehensive support throughout the clinical trial lifecycle.
Resonant has finalized the acquisition of Labfish to bolster its European footprint and clinical trial service offerings. The deal integrates Labfish's specialized calibration expertise and IOR/EOR coverage into Resonant's global platform, streamlining the clinical study lifecycle for international clients.
The acquisition is designed to expand Resonant's European footprint and integrate Labfish's specialized calibration and IOR/EOR capabilities into a unified global clinical solutions platform.